Preliminary Data from Phase 1b and Open-Label Phase 2 Studies of AL001 for People with Frontotemporal Dementia was Promising; Alector Inc. (NASDAQ:ALEC) Reported

While this may not be known to many, Frontotemporal dementia (FTD) is one of the rare forms of dementia, which has a rapid progression. It is more common in people less than 65 years old and comes in multiple heritable forms. FTD with a progranulin gene (GRN) mutation takes about 5%-10% of all FTD cases. However, as severe as it may sound, Alector Inc. (NASDAQ:ALEC) is determined to turn around the situation.

In its pursuit to eradicate neurodegenerative diseases, the company has developed a prospective treatment for people with FTD. AL001 is in its Phase 1b and open-label Phase 2 studies, and from the preliminary data announced by the company, it is a promising candidate.

Through a virtual presentation at the virtual 2020 Alzheimer’s Association International Conference (AAIC), the chief medical officer of Alector, Robert Paul, did emphasize the substantial progress pointing out that they were now headed to rapid initiation of a pivotal Phase 3 trial.

Effects of the COVID-19 Pandemic on the Study

The instant hit and rapid spread of the COVID-19 was a blow for many business operations, and Alector did feel the effects, particularly on the Phase 2 study. The company closed several sites, and some bits of the study had to be carried out remotely. During remote patient assessments, some participants of the study missed a dose of AL001.

However, the biotech is slowly getting back and is working closely with participants, investigators, and other sites to avert any impending effects of the pandemic.

It Is Only a Matter of Time before AL001 is adopted as the Treatment of Choice

With its wide portfolio of programs, Alector has taken control of the development of neurology, immunology, and human genetics.

The company envisions a time in the world where every person will have the ability to retain the full functioning of their brains and cognitive faculties.

However, Arnon Rosenthal, the CEO, says that they are optimistic about managing the devastating disease. Rosenthal is banking on the preliminary findings, which showcased AL001 as a well-tolerated and possible long-term treatment.